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Summary.-Bleomycin is a chemotherapeutic drug used primarily in the treatment
of squamous-cell carcinoma, while misonidazole is an effective radiosensitizer and
potent cytotoxic agent selectively affecting hypoxic cells.
V79 Chinese hamster cells were used to investigate the cytotoxicity of bleomycin
(BLM) under aerated and hypoxic conditions as a function of drug concentration.
At a lowered temperature of 17*5'C, or at an elevated temperature of42-50C, hypoxic
cells are more sensitive to killing by BLM than aerated cells. At either of these
temperatures, progression through the cell cycle is inhibited. However, at 37-5°C,
mimicking a clinical situation, the sensitivities are reversed, and hypoxic cells are
appreciably more resistant. Although many factors are involved, the major reason
for this is that aerated cells are cycling while hypoxic cells are not. Aerated cells
can progress into phases of the cell cycle where they are more sensitive to killing by
BLM.
Misonidazole (=Ro-07-0582) was used in combination with BLM, since its mode
of action has been shown to be specific for killing hypoxic cells. Its concomitant use
with BLM could be of potential use in chemotherapy when confronted with the
hypoxic cell component of solid tumours.
BLEOMYCIN (BLM) is an antineoplastic
agent which was discovered in 1966
(Umezawa et al., 1966) and introduced
into clinical use in the United States in
1970. It has been reported to be useful in
treating squamous-cell carcinoma of the
head and neck, and also for treatment of
lymphomas and testicular carcinoma
(Blum et al., 1973; De Vita, Serpick and
Carbone, 1970; Ichikawa, Nakano and
Hirokawa, 1969; Ichikawa, Nakano and
Krokawa, 1970; Takeuchi, 1976). Although
BLM is usually said to be cell-cycle-phase
non-specific because it causes some cell
killing at all phases of the cell cycle, cells
in M and G2 are more sensitive to the
drug, and atlowdoses itreversiblyinhibits
cell progression at the S-G2 boundary
(Barranco et at., 1973; Clarkson and
Humphrey, 1976; Watanabe et al., 1974).
Since the majority of antineoplastic
drugs kill actively dividing cells, they
probably are not as effective in killing
cells in solid tumours which are remote
from the vascular supply, deficient in
molecular oxygen, and unlikely to be in
active cell cycle. In this case, the use of
one of the new generation of electron-
affinic drugs, which selectively affect
hypoxic cells, could be of significant value
in killing those cells which escape the
action of other antineoplastic agents. A
number of such drugs, particularly the
nitroimidazole, misonidazole (Adams,
1973; Stratford and Adams, 1977; Hall
and Biaglow, 1977), could well be a
nominee for inclusion in a multi-drug
chemotherapy regimen. Misonidazole
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(- Ro-07-0582) is selectively cytotoxic
towards hypoxic cells, and would therefore
avoid further damage to normal aerated
cells in tissues already treated with other
antineoplastic agents. The nitroimidazoles
have already found a place in radio-
therapy because they selectively sensitize
hypoxic cells. The fact that they are also
selectively cytotoxic to hypoxic cells
which may be non-cycling makes them
potentially of interest in chemotherapy
as well.
MATERIALS AND METHODS
V79 Chinese hamster cells were used
throughout this series of experiments. The
strain was originally obtained from Dr M. M.
Elkind at Argonne National Laboratory, but
has been maintained at Columbia University
for about 7 years. Standard culturetechniques
were used, with the cells grown in GIBCO
FIO culture medium, supplemented with 10%
foetal calf serum, and antibiotics (Ham and
Puck, 1962). (Under these conditions, routine
growth curves showed that the population
doubling time is about 10 h.)
For preliminary experiments to test the
toxicity of BLM with aerated cells, known
numbers of cells were inoculated into 60 mm
Falcon plastic Petri dishes, allowed to attach
overnight at 37 5°C, before BLM was added
at a range of concentrations. After a 30 min
exposure at 37 5°C, the drug was removed, the
Petri dishes rinsed and fresh growth medium
added. An 8-day incubation at 37 5°C was
then allowed for colony formation.
For drug experiments under hypoxia, cells
were treated in suspension in glass ampoules.
To induce hypoxia, large numbers of cells
were crowded into a small volume ofmedium
so that 02 was reduced to a low level by cell
metabolism and respiration. This widely
used method has been described in detail
elsewhere (Hall, Lehnert and Roizin-Towle,
1974). Proof that this system produces
adequate levels of hypoxia is evidenced by
an oxygen enhancement ratio (OER) of
3-2 when aerated and hypoxic cells are
exposed to acute doses of60Co y rays. For the
short periods of time used in these experi-
ments, the plating efficiencies for both
groups of cells remained high and relatively
unaffected by the experimental conditions
employed.
The essential steps for producing hypoxic
cells were as follows: Cells from a number of
actively growing. partially confluent, stock
flasks were harvested by trypsinization,
washed to remove excess trypsin, counted
with a Coulter electronic counter and pre-
pared into a suspension so that the final cell
concentration in the glass ampoules would
contain 2 x 106 cells/ml. At this point, BLM
or misonidazole was added to the cell sus-
pension to achieve the final drug concentra-
tion required by the plan of the experiment.
In one series of experiments the effect of
combining 5 mm misonidazole and 4 concen-
trations ofBLM was studied, and in this case
both drugs were added together at this stage.
A series of long-necked 1 ml glass ampoules
were filled from this cell suspension, flushed
with pure N2 containing 5% CO2 to remove
the air from the space above the cells, and
then heat-sealed. The ampoules were then
continuously shaken and tumbled to keep the
cells in suspension, and the temperature
elevated to 37 5°C for 1 h to allow the
residual 02 in the medium to be consumed by
cell respiration. A parallel series of ampoules
was filled with cells at a concentration of 104/
ml; these were gassed with a mixture of air
and 5% CO2 before being heat-sealed.
Because of the lower number of cells, these
ampoules remained aerated throughout. The
same drug concentrations were used with
aerated as with hypoxic cells.
After the sealing of all of the ampoules
and the 1 h treatment at 37-5°C, they
received various temperature exposures
according to the plan ofthe particular experi-
ment. Control ampoules were subject to the
same handling procedures and temperature
changes except that no drug was present.
At the conclusion of the appropriate
treatments, each ampoule was vigorously
agitated on a vortex mixer, before being
opened and various aliquots of the cell
suspension replated into tissue culture flasks
containing fresh growth medium. After an
incubation period of 8 days at 37 5°C, the
cells were fixed and stained, and the number
ofmacroscopic colonies per flask counted by a
projection technique. Ampoules containing
cells with concentrations of BLM higher than
5 ,ug/ml were washed first with saline before
resuspension in fresh media. This was deemed
necessary as concentrations of BLM in the
medium greater than 1 ,tg/ml retarded cell
growth.
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RESULTS
Toxicity curves for bleomycin with aerated
attached cells
Fig. 1 shows the fraction of cells
surviving a 30 min treatment with BLM
as a function of drug concentration.
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Effect of BLM on aerated and hypoxic cells
at 3 different temperatures
Fig. 2 shows the results of a 4 h treat-
ment of aerated and hypoxic cells at
37.5°C. Each point represents the pooled
data from 3 repeat experiments. The
range ofconcentrations ofBLM chosen for
these experiments was 5-250 ,ug/ml. At
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FIG. 1. Effect on asynchronous V79 hamster
cells of a 30 min exposure to bleomycin at
37.50C (0). The biphasic survival curve
suggests the presence in the population of
cells with varying sensitivity. Also shown
(*) are comparable data for a different cell
line by Barranco and Humphrey (1971).
Previously published data by Barranco
and Humphrey (1971) for CHO (Chinese
hamster ovary) cells are also plotted for
comparison. These experiments demon-
strate the typical biphasic reponse to
BLM exhibited by many cell lines in
vitro. The V79 curve is biphasic with 65%
of the cell population defined by a Do of
63*5 ,ug/ml and the more resistant part
of the population by a Do of 237 ,g/ml.
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FIG. 2.-Survival curves for V79 hamster cells
treated with graded doses ofBLM for 4 h at
37-50C under aerated (-) and hypoxic (U)
conditions.
this temperature, aerated cells are signifi-
cantly more sensitive to BLM. At drug
concentrations of 5 or 10 ,ug/ml, the
fraction of cells surviving a 4 h treatment
is lower under aerated than hypoxic
conditions by a factor of 3; this factor
increases to 10 for a higher drug concen-
tration of 250 ,ug/ml. Fig. 3 shows the
results of similar experiments performed
at 17.50C for 4 h. In this case, with cell
cycling arrested by the drop in tempera-
ture, the sensitivities of aerated and
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FIG. 3. Survival curves for V79 hamster cells
treated with increasing doses ofBLM for 4 h
at 17-50C under aerated (0) and hypoxic
(U) conditions.
hypoxic cells are reversed, with hypoxic
cells being most sensitive to BLM. At
an elevated temperature of 42 5°C, the
hypoxic cells are again more sensitive
than aerated cells, as can be seen from
Fig. 4. The cytotoxicity of BLM is
enhanced by elevated temperatures, so
that at 42-5°C the treatment time was
restricted to 1 h, and the maximum drug
concentration that could be used was
25 p,g/ml.
The results of experiments involving a
combination of BLM and misonidazole
are shown in Fig. 5. In these experiments,
both aerated and hypoxic cells received a
4 h treatment at 37-5°C with concentra-
tions ofBLM ranging from 5 to 100 p,g/ml,
or the same concentration of BLM with
the addition of the nitroimadazole at a
concentration of 5 mm. This figure illus-
trates dramatically that, while the addi-
CONCENTRATION OF BLEOMYCIN (pg/ml)
FiG. 4.- Effects on V79 hamster cells of
graded doses of BLM in combination with
hyperthermia (42 5°C) for 1 h under
aerated (0) and hypoxic (-) conditions.
The hyperthermia alone caused appreciable
cell killing (SF = 0.3) but this was allowed
for in the calculation ofthe cytotoxic effects
of the BLM treatments.
tion of the nitroimidazole had no effect
on the response of aerated cells treated
with BLM, it reduced the survival of
hypoxic cells by 2 orders of magnitude.
DISCUSSION
The biphasic dose-response curve for
cells treated with BLM, shown in Fig. 1,
suggests the presence of sensitive and
resistant moieties in the asynchronously
growing cell population. While this may
partly account for the observation, it is
inadequate as an interpretation because
synchronized cells also show a biphasic
response. Terasima et al. (1976) suggested
that the biphasic survival curve results
from the fact that BLM kills cells exponen-
tially and then induces a resistant fraction.
Following the removal of the drug the
resistance is reduced and repeated doses
exert further lethal effects on the remain-
ing viable cells.
The experiments reported in the present
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FIG. 5. Effects of BLM on survival of V79
hamster cells treated for 4 h at 37-5°C
under aerated (circles) and hypoxic
conditions (squares). Closed symbols BLM
alone; open symbols BLM + 5 mM misoni-
dazole. The addition of misonidazole
reduces the survival ofhypoxic cells treated
with BLM, but has no effect on aerated
cells.
communication were primarily concerned
with studying the effects of BLM on
aerated and hypoxic cells. At 37 5°C,
hypoxic cells appear to be less sensitive to
BLM than aerated cells. A possible and
most likely explanation for this difference
is that aerated cells at this temperature
continue to progress through the cell cycle
and can enter a more drug-sensitive
phase, whereas hypoxic cells cannot be-
cause of their restricted cell progression.
Experiments performed by Geard et al.
(1977) with V79 cells and techniques
similar to those used in our study, showed
that only 14% of cells have moved into
mitosis in 6 h after 1 h hypoxia, compared
to about 40% for aerated cells. Increasing
time in hypoxia to 5 h resulted in 9% of
the cell population moving into mitosis.
It is justifiable to say, then, that hypoxia
severely retards cell cycling and may
account in part for the differential res-
ponse ofaerated and hypoxic cells to BLM.
Evidence to support the idea that cell
progression accounts in large part for the
increased response of aerated cells over
hypoxic cells at 37 5°C comes from the
experiments performed at elevated or
lowered temperatures. At the lowered
temperature (17.5°C), cell division and
cell progression through the cycle are
completely arrested. At the elevated
temperature (42 5°C), not only are cells
inhibited from progression through the
cycle, but the treatment time of 1 h is
too short to allow a significant shift in the
population sensitivity by cell cycling. In
either case, with cell progression essen-
tially eliminated, the order of sensitivities
is reversed and hypoxic cells become more
sensitive to BLM (Figs. 3 and 4). Neverthe-
less, at normal body temperature, hypoxic
cells appear to be relatively resistant to
BLM. To reduce hypoxic cell survival at
37 5°C, which is the temperature of
relevance to the clinical situation, misoni-
dazole was used in combination with
BLM. Although this nitroimidazole was
the fruit of an intense search for an
hypoxic cell radiosensitizer (Adams, 1973;
Chapman et al., 1974; Sheldon, Foster and
Fowler, 1974) it has since been shown to
be a cytotoxic agent as well, specifically
with regard to hypoxic cells (Hall and
Roizin-Towle, 1975). When hypoxic cells
treated with BLM were simultaneously
treated with 5 mm misonidazole (Fig. 5)
their level of survival was reduced to a
surviving fraction far below that of
aerated cells. This could considerably
augment chances for a remission or cure
when treating solid tumours containing
hypoxic cells. The suggestion has been
made more than once that misonidazole
would be a logical drug for inclusion in a
chemotherapy protocol (Stratford and
Adams, 1977; Sutherland et al., 1976).
Fig. 5 clearly demonstrates its enhance-
ment ofhypoxic cell killing in combination
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with the widely used drug BLM. The fact
that it is cell-cycle-phase non-specific,
and selectively cytotoxic towards hypoxic
cells, means that it is effectively comple-
mentary in its action to drugs such as
BLM.
V7arious experiments have investigated
the effects of BLM on dividing and non-
dividing cells, using plateau-phase cells
as a model. Hahn et al. (1973) found a very
close quantitative relation between their
in ?vitro results with CHO plateau-phase
cells and the in vivo EMT 6 tumour system,
which led them to classify BLM as an
agent which preferentially kills non-
cycling cells. This effect, however, is not
universal. For the CHO cells used by
Barranco et al. (1973) the sensitivity of
the plateau phase was 10 times that of the
log phase whereas the V79-derived cell
line showed less sensitivity in plateau
phase than in the log phase. Although for
the sake of simplicity it is convenient to
classify a drug as specific for dividing or
non-dividing cell populations, in reality
the ultimate response is more often than
not determined by the cell line itself.
Non-dividing populations of cells in
plateau phase or acute hypoxia may have
the common property that they are non-
cycling. However, chemically they are
most likely not the same. The results in
Fig. 2 demonstrate that hypoxic cells are
less sensitive to BLM than are aerated
cells, and that part of this difference is a
consequence of arrested cell progression.
This does not rule out other factors
involved in this response, such as differ-
ences between aerated and hypoxic cells in
rate of uptake of drug, rate of drug in-
activation or ability to repair DNA. The
condition in the glass ampoules which
results from hypoxia produced by cell
metabolism is suboptimal from a tissue-
culture standpoint, but may represent a
good model for the conditions which
prevail in the hypoxic regions of a tumouir
tn vivo.
The experiments performed at 42 5°C
showed that the cytotoxicity of BLM is
greatly enhanced at an elevated tempera-
ture. This lends further support to the
previous reports by Hahn, Brown and
Har-Kedar, (1975) and Twentyman (1976).
In addition, Braun and Hahn (1975)
showed that I h at 43°C resulted in a
fixation of the potentially lethal damage
(PLD) in cells treated with BLM. This
suppression of PLD repair by hyper-
thermia is important in the context of
combination treatments, since several
studies have shown that a large amount of
PLD repair occurs rapidly following
treatments with BLM (Ray et al., 1973;
Hahn et al., 1973; Barranco and Humph-
rey, 1976).
Future planning for tumour treatment
could very probably involve a multifaceted
design incorporating the most expedient
use of drugs, radiation and possibly
hyperthermia. Since misonidazole has
proved to be effective in dealing with
hypoxic cells, and has already shown
encouraging results in combination with
radiotherapy, its low systemic toxicity and
sensitizing properties could well make it a
candidate for futuire use in any one or all
of these disciplines.
The bleomyciii used for these experimnents was
kindly supplie(i by Bristol Laboratories ofSyracuse,
New York, and the mnisonidlazole donated bv Roche
Products, Welwyni Garden City, U.K.
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